P230009/S021: Shield
FDA’s recorded scope: approval of a secondary vendor
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 26 FDA records to the applicant name Guardant Health, Inc.. It includes 3 original PMA approvals. 9 entries are PMA supplements. 14 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Aug 7, 2020 to Oct 5, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code PHP appears in 13 of the 26 linked filings. The collection spans 2 FDA product codes and 3 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P230009, with 13 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: 3000 Hanover St., Palo Alto, CA, 94304. Recorded on P230009/S021, decision dated Oct 5, 2026.
System, Colorectal Neoplasia, Dna Methylation And Hemoglobin Detection; Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System.
FDA’s recorded scope: approval of a secondary vendor
FDA’s recorded scope: Approval for expanding the intended use and indications for use of Guardant360 CDx to include a companion diagnostic indication for the detection of ESR1 mutations in Breast Cancer (BC) patients who may benefit from treatment with INLURIYO (imlunestrant) in combination with VERZENIO (abemaciclib).
FDA’s recorded scope: manufacturing changes
FDA’s recorded scope: Approval for expanding the indications for use to include a companion diagnostic claim for the detection of ESR1 mutations in patients with breast cancer who may benefit from treatment with ETCAMAH (camizestrant).
FDA’s recorded scope: Approval of the clinical protocol titled Clinical Validation of Guardant360 CDx for the Selection of First-Line Non-Small Cell Lung Cancer (NSCLC) Patients with ERBB2/HER2 TKD-Activating Mutations for Zongertinib Therapy (Protocol No. 01-LU-038, PLP-003941 R1, Version 1.0) for the post-approval study.
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ShieldP230009/S021 | Guardant Health, Inc. | PMA supplement | Oct 5, 2026 | FDA |
Guardant360 CDxP200010/S029 | Guardant Health, Inc. | PMA supplement | Sep 18, 2026 | FDA |
ShieldP230009/S020 | Guardant Health, Inc. | PMA supplement | Sep 16, 2026 | FDA |
Guardant360 CDxP200010/S024 | Guardant Health, Inc. | PMA supplement | Sep 4, 2026 | FDA |
Guardant360 CDxP200010/S032 | Guardant Health, Inc. | PMA supplement | Aug 7, 2026 | FDA |
ShieldP230009/S010 | Guardant Health, Inc. | PMA supplement | Jul 22, 2026 | FDA |
ShieldP230009/S018 | Guardant Health, Inc. | PMA supplement | Jul 21, 2026 | FDA |
Guardant360 CDxP200010/S030 | Guardant Health, Inc. | PMA supplement | Jul 14, 2026 | FDA |
Guardant360 CDxP200010/S031 | Guardant Health, Inc. | PMA supplement | Jul 6, 2026 | FDA |
Guardant360 Liquid CDxP250027/S001 | Guardant Health, Inc. | PMA supplement | Jul 6, 2026 | FDA |
Guardant360 CDxP200010/S027 | Guardant Health, Inc. | PMA supplement | Jun 10, 2026 | FDA |
ShieldP230009/S016 | Guardant Health, Inc. | PMA supplement | May 21, 2026 | FDA |
Guardant360 Liquid CDxP250027 | Guardant Health, Inc. | PMA approval | May 19, 2026 | FDA |
Guardant360 CDxP200010/S025 | Guardant Health, Inc. | PMA supplement | May 1, 2026 | FDA |
ShieldP230009/S014 | Guardant Health, Inc. | PMA supplement | Apr 15, 2026 | FDA |
ShieldP230009/S015 | Guardant Health, Inc. | PMA supplement | Apr 1, 2026 | FDA |
ShieldP230009/S013 | Guardant Health, Inc. | PMA supplement | Feb 4, 2026 | FDA |
Guardant360 CDxP200010/S026 | Guardant Health, Inc. | PMA supplement | Jan 15, 2026 | FDA |
Guardant360 CDxP200010/S028 | Guardant Health, Inc. | PMA supplement | Dec 29, 2025 | FDA |
ShieldP230009/S011 | Guardant Health, Inc. | PMA supplement | Dec 22, 2025 | FDA |
ShieldP230009/S009 | Guardant Health, Inc. | PMA supplement | Oct 30, 2025 | FDA |
Guardant360 CDxP200010/S021 | Guardant Health, Inc. | PMA supplement | Sep 25, 2025 | FDA |
ShieldP230009/S008 | Guardant Health, Inc. | PMA supplement | Sep 23, 2025 | FDA |
ShieldP230009/S007 | Guardant Health, Inc. | PMA supplement | Jul 23, 2025 | FDA |
ShieldP230009 | Guardant Health, Inc. | PMA approval | Jul 26, 2024 | FDA |
Guardant360 CDxP200010 | Guardant Health, Inc. | PMA approval | Aug 7, 2020 | FDA |
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.